Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PROK
PROK logo

PROK Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Prokidney Corp (PROK) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.600
1 Day change
-9.60%
52 Week Range
7.130
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Prokidney Corp (PROK) is not a strong buy for a beginner, long-term investor at this time. The technical indicators show a bearish trend, insiders are selling heavily, and there are no positive catalysts or significant trading signals to support an immediate investment. Additionally, the company's financial performance shows revenue growth but declining net income and EPS, which raises concerns about profitability.

Technical Analysis

The stock is in a bearish trend with MACD below zero and negatively expanding, RSI indicating oversold conditions at 19.944, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The price is near the key support level of 1.776, with resistance at 2.024. The stock has a 70% chance of minor declines in the next day and month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
11
Buy
5

Positive Catalysts

  • Revenue increased significantly by 196.05% YoY in 2025/Q4.

Neutral/Negative Catalysts

  • Insiders are selling heavily, with a 503.05% increase in selling activity over the last month. Net income and EPS have declined YoY, and there are no recent positive news or significant trading signals. No recent congress trading activity.

Financial Performance

In 2025/Q4, revenue increased to $225,000 (up 196.05% YoY), but net income dropped to -$19,231,000 (down -9.62% YoY), and EPS fell to -0.14 (down -17.65% YoY). Gross margin remained stable at 100%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data provided.

Wall Street analysts forecast PROK stock price to rise
3 Analyst Rating
Wall Street analysts forecast PROK stock price to rise
1 Buy
1 Hold
1 Sell
Hold
Current: 1.770
sliders
Low
1
Averages
5.33
High
12
Current: 1.770
sliders
Low
1
Averages
5.33
High
12
H.C. Wainwright
Joseph Pantginis
Buy
initiated
$12
AI Analysis
2025-12-16
Reason
H.C. Wainwright
Joseph Pantginis
Price Target
$12
AI Analysis
2025-12-16
initiated
Buy
Reason
H.C. Wainwright analyst Joseph Pantginis initiated coverage of ProKidney with a Buy rating and $12 price target. The company is pioneering an approach to postponing progressive kidney dysfunction, the analyst tells investors in a research note. The firm says ProKidney is a late clinical-stage biopharmaceutical company developing rilparencel, an investigational autologous cell therapy targeting patients with moderate to severe chronic kidney disease and type 2 diabetes. It believes rilparencel has the potential to redefine the therapeutic landscape of chronic kidney disease.
UBS
Buy
upgrade
$4 -> $8
2025-07-15
Reason
UBS
Price Target
$4 -> $8
2025-07-15
upgrade
Buy
Reason
UBS raised the firm's price target on ProKidney to $8 from $4 and keeps a Buy rating on the shares. Recent data from a Phase 2 trial of rilparencel show stabilization of kidney function in patients with diabetes and advanced chronic kidney disease, the analyst tells investors in a research note. ProKidney expects to meet with the FDA in the near-term to align on eGFR slope as a potential acceptable Phase 3 surrogate endpoint for accelerated approval in advanced CKD, which should give clarity on a potential readout.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PROK
Unlock Now

People Also Watch